BRAF inhibitor therapy in HCL.

Sascha Dietrich, Thorsten Zenz

Journal: Best practice & research. Clinical haematology 2016;28(4):246-52

PMID: 26614903

Full Text on Elsevier Science View on PubMed

Abstract

Targeted treatment approaches are transforming the therapeutic landscape of cancer care. The discovery of the BRAF V600E mutation in most cases of classical hairy cell leukemia opens up unique opportunities for tumor specific treatment of HCL targeting the MEK/ERK signaling pathway. The discovery and biological implications of BRAF V600E in HCL are summarized to form a basis for our current understanding of the potential for clinical exploitation. There is overwhelming clinical evidence for activity of inhibitors of BRAF in the disease. The review will review current trial activity as well as discuss novel trial concepts exploiting targeted treatment focusing on BRAF inhibition in HCL.

Address: Department of Translational Oncology, National Center for Tumor Diseases (NCT) and German Cancer Research Center (DKFZ), Im Neuenheimer Feld 460, 69120 Heidelberg, Germany; Department of Medicine V, Heidelberg University Medical Center, Heidelberg, Germany; Genome Biology Unit, European Molecular Biology Laboratory, Heidelberg, Germany.; Department of Translational Oncology, National Center for Tumor Diseases (NCT) and German Cancer Research Center (DKFZ), Im Neuenheimer Feld 460, 69120 Heidelberg, Germany; Department of Medicine V, Heidelberg University Medical Center, Heidelberg, Germany. Electronic address: [email protected].

DOI: 10.1016/j.beha.2015.10.001

Link outs

Free resources

Miscellaneous:

https://assays.cancer.gov/CPTAC-2786

Research Materials:

https://antibodies.cancer.gov/detail/CPTC-BRAF-6

Subscription / membership required

Full Text Sources:

MeSH Terms: Antineoplastic Agents, Clinical Trials as Topic, Gene Expression Regulation, Leukemic, Humans, Imidazoles, Indoles, Leukemia, Hairy Cell, MAP Kinase Signaling System, Molecular Targeted Therapy, Mutation, Neoplasm, Residual, Oximes, Proto-Oncogene Proteins B-raf, Remission Induction, Sulfonamides, Survival Analysis, Vemurafenib